Nuwellis (NUWE) Proxy filing summary
Event summary combining transcript, slides, and related documents.
Proxy filing summary
26 Jun, 2026Executive summary
Special meeting scheduled for July 24, 2026, to vote on three key proposals via virtual webcast.
Proposals include approval of warrant exercises, a reverse stock split, and potential adjournment to solicit more proxies.
Board unanimously recommends voting in favor of all proposals.
Only shareholders of record as of June 5, 2026, are eligible to vote.
Voting matters and shareholder proposals
Proposal 1 seeks approval for issuance of up to 2,396,709 shares upon exercise of warrants from a June 2026 financing and repriced outstanding warrants, in compliance with Nasdaq rules.
Proposal 2 requests approval for a reverse stock split at a ratio between 1-for-5 and 1-for-70, at the Board's discretion, to maintain Nasdaq listing compliance.
Proposal 3 authorizes adjournment of the meeting to solicit additional proxies if needed for Proposals 1 or 2.
Each proposal requires a majority of votes cast for approval; abstentions and broker non-votes generally do not affect outcomes.
Board of directors and corporate governance
Board retains discretion on the timing and ratio of the reverse stock split within twelve months of approval.
Board may abandon the reverse split if deemed not in the best interest of shareholders.
Board and management have minimal direct interests in the proposals, aside from their own shareholdings.
Latest events from Nuwellis
- Votes sought for warrant issuance, reverse split, and adjournment to support Nasdaq compliance.NUWE
Proxy filing7 Jul 2026 - Best-efforts offering targets $4.4M for working capital, with high dilution and ongoing losses.NUWE
Registration filing4 Jun 2026 - Pediatric and critical care growth, innovation, and operational discipline drive revenue momentum.NUWE
Investor presentation2 Jun 2026 - Offering up to $4.4M in equity and warrants, with high dilution and operational risks.NUWE
Registration filing29 May 2026 - Up to $4.4M sought via equity and warrants to fund operations amid high product and financial risk.NUWE
Registration filing22 May 2026 - Revenue up 26% to $2.4M, gross margin 70.1%, net loss $4.5M, with new patents and capital needs.NUWE
Q1 202615 May 2026 - Updated share count, board changes, and voting details for the April 2026 Annual Meeting.NUWE
Proxy filing6 Apr 2026 - Board seeks approval for director elections and auditor ratification, emphasizing governance.NUWE
Proxy filing2 Apr 2026 - Q4 revenue and margin gains, strategic moves, and new leadership set up 2026 growth.NUWE
Q4 202520 Mar 2026